An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors - Trial NCT05976334
Access comprehensive clinical trial information for NCT05976334 through Pure Global AI's free database. This Phase 1 trial is sponsored by Takeda and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Takeda
Timeline & Enrollment
Phase 1
Oct 31, 2023
Apr 30, 2025
Primary Outcome
Cumulative Percentage of Urinary Recovery,Cumulative Percentage of Fecal Recovery,Cumulative Percentage of Combined Recovery,Percentage Of Recovered Total Radioactivity (TRA) In Urine And Feces
Summary
The main aim of this study is to assess how the human body of adults with advanced or
 metastatic solid tumors absorbs, distributes, metabolizes and excretes subasumstat following
 a single 1 hour infusion of subasumstat.
 
 The study consists of two parts. In Part A, participants will receive a single infusion of
 C14 radiolabeled subasumstat. In Part B, participants will receive subasumstat treatment for
 up to 1 year.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05976334
Non-Device Trial